Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34090364)

  • 1. Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours.
    Dhaka B; Sabarinathan R
    BMC Cancer; 2021 Jun; 21(1):669. PubMed ID: 34090364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.
    Zhu J; Sammons MA; Donahue G; Dou Z; Vedadi M; Getlik M; Barsyte-Lovejoy D; Al-awar R; Katona BW; Shilatifard A; Huang J; Hua X; Arrowsmith CH; Berger SL
    Nature; 2015 Sep; 525(7568):206-11. PubMed ID: 26331536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
    Barta JA; Pauley K; Kossenkov AV; McMahon SB
    Carcinogenesis; 2020 Mar; 41(1):67-77. PubMed ID: 31067569
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Watanabe S; Tsuchiya K; Nishimura R; Shirasaki T; Katsukura N; Hibiya S; Okamoto R; Nakamura T; Watanabe M
    Mol Cancer Res; 2019 Jul; 17(7):1459-1467. PubMed ID: 30988165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
    Valenti F; Ganci F; Fontemaggi G; Sacconi A; Strano S; Blandino G; Di Agostino S
    Oncotarget; 2015 Mar; 6(8):5547-66. PubMed ID: 25650659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
    Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
    Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
    Ghaleb A; Padellan M; Marchenko N
    Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.
    Yan W; Liu G; Scoumanne A; Chen X
    Cancer Res; 2008 Aug; 68(16):6789-96. PubMed ID: 18701504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide estrogen receptor β chromatin binding in human colon cancer cells reveals its tumor suppressor activity.
    Indukuri R; Jafferali MH; Song D; Damdimopoulos A; Hases L; Zhao C; Archer A; Williams C
    Int J Cancer; 2021 Aug; 149(3):692-706. PubMed ID: 33754337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional activities of mutant p53: when mutations are more than a loss.
    Kim E; Deppert W
    J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
    Bossi G; Lapi E; Strano S; Rinaldo C; Blandino G; Sacchi A
    Oncogene; 2006 Jan; 25(2):304-9. PubMed ID: 16170357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.
    Lü Y; Cho T; Mukherjee S; Suarez CF; Gonzalez-Foutel NS; Malik A; Martinez S; Dervovic D; Oh RH; Langille E; Al-Zahrani KN; Hoeg L; Lin ZY; Tsai R; Mbamalu G; Rotter V; Ashton-Prolla P; Moffat J; Chemes LB; Gingras AC; Oren M; Durocher D; Schramek D
    Mol Syst Biol; 2024 Jun; 20(6):719-740. PubMed ID: 38580884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated Chromatin Accessibility and Transcriptome Landscapes of Doxorubicin-Resistant Breast Cancer Cells.
    Wang X; Yan J; Shen B; Wei G
    Front Cell Dev Biol; 2021; 9():708066. PubMed ID: 34395436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53 in colon cancer.
    Nakayama M; Oshima M
    J Mol Cell Biol; 2019 Apr; 11(4):267-276. PubMed ID: 30496442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kruppel-like factor 2 mediated anti-proliferative and anti-metastasis effects of simvastatin in p53 mutant colon cancer.
    Lu L; Huang W; Hu W; Jiang L; Li Y; Wu X; Yuan D; Li M
    Biochem Biophys Res Commun; 2019 Apr; 511(4):772-779. PubMed ID: 30833076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic.
    Kadosh E; Snir-Alkalay I; Venkatachalam A; May S; Lasry A; Elyada E; Zinger A; Shaham M; Vaalani G; Mernberger M; Stiewe T; Pikarsky E; Oren M; Ben-Neriah Y
    Nature; 2020 Oct; 586(7827):133-138. PubMed ID: 32728212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53.
    Simões ML; Hockley SL; Schwerdtle T; Gamboa da Costa G; Schmeiser HH; Phillips DH; Arlt VM
    Toxicol Appl Pharmacol; 2008 Oct; 232(1):86-98. PubMed ID: 18639569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor suppressor protein p53 exerts negative transcriptional regulation on human sodium iodide symporter gene expression in breast cancer.
    Kelkar MG; Thakur B; Derle A; Chatterjee S; Ray P; De A
    Breast Cancer Res Treat; 2017 Aug; 164(3):603-615. PubMed ID: 28528452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.